IQVIA Holdings Inc. (IQV) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with revenue and EPS exceeding guidance, substantial share repurchases, and optimistic outlooks for demand in outsourced clinical development and Commercial Solutions. Despite some economic uncertainties, the constructive demand environment and increased AI-driven demand in Commercial Solutions are positive indicators. Share repurchases and solid cash flow further enhance shareholder value. The Q&A session confirms stable demand and growth drivers, with no significant negative trends highlighted. Overall, the sentiment is positive, likely resulting in a stock price increase of 2% to 8%.
Key Financial Performance
Total Revenue $4.151 billion for the first quarter, grew 8.4% on a reported basis and 6.0% at constant currency. Growth includes about 2 points of contribution from acquisitions.
Commercial Solutions Revenue $1.754 billion for the first quarter, up 11.6% on a reported basis and 8.5% at constant currency. Growth driven by new product launches and increased breadth of services utilized by clients.
R&D Solutions Revenue $2.397 billion for the first quarter, up 6.2% on a reported basis and 4.2% at constant currency. Growth attributed to better-than-expected reported and organic revenue growth.
Adjusted EBITDA $932 million for the first quarter, representing growth of 5.5% year-over-year.
Adjusted Diluted EPS $2.90 for the first quarter, representing growth of 7.4% year-over-year. Exceeded the high end of guidance range.
R&D Solutions Net New Bookings $2.5 billion for Q1 2026, a double-digit increase year-over-year. Growth attributed to solid service fee bookings and consistent cancellation rates.
R&D Solutions Backlog $34.2 billion at the end of the quarter, a mid-single digit increase year-over-year. $8.9 billion of this backlog will convert to revenue in the next 12 months, representing nearly 8% growth year-over-year.
Free Cash Flow $491 million for the first quarter, a 15% increase year-over-year. Growth driven by strong cash flow from operations and controlled capital expenditures.
Share Repurchases $552 million of shares repurchased in the first quarter, leaving approximately $1.2 billion of repurchase authorization remaining.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI Solutions: IQVIA unveiled IQVIA.ai, an AI portal and marketplace for life sciences, with 192 AI agents deployed covering 64 use cases. 19 of the top 20 pharma companies are using these agents.
AI-Driven Analytics: IQVIA secured contracts with top pharma companies to modernize performance reporting and provide scalable AI-ready data foundations.
Strategic Collaborations: Collaborations with Pfizer, Boehringer Ingelheim, and others to enhance commercial operations and product launches using AI and data services.
Market Expansion in Europe: Strategic regional promotion agreement with Pfizer covering 23 countries in Europe.
Global Commercial Intelligence: Collaboration with Boehringer Ingelheim to upgrade global commercial operations across 59 countries.
Clinical Trial Optimization: AI solutions used to optimize trial design and execution, reducing timelines and improving quality.
Operational Efficiency: AI agents embedded in delivery models for faster study execution and reduced errors.
Strategic Partnerships: Collaboration with Duke Clinical Research Institute to advance clinical research in obesity and cardiometabolic conditions.
AI Integration: IQVIA's long-term strategy to integrate AI into operations and solutions, positioning as an AI-native company in life sciences.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Pass-through bookings: Unusually low pass-through bookings in the quarter due to the mix of clinical trial indications, which could impact revenue recognition and financial performance.
Net debt: High net debt of $13.886 billion and a net leverage ratio of 3.62x trailing 12 months adjusted EBITDA, which could pose financial risks and limit flexibility.
Regulatory compliance: Potential risks associated with maintaining compliance with privacy, regulatory, and integrity standards, especially as AI solutions are scaled.
AI integration: Challenges in embedding AI agents into workflows and ensuring their effectiveness, which could impact operational efficiency and client satisfaction.
Client cancellations: Although cancellations were within the normal range, any increase in cancellations could negatively affect bookings and revenue.
Economic uncertainties: Dependence on large pharma and EVP funding, which could be impacted by broader economic conditions or changes in client budgets.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: IQVIA expects full-year 2026 revenue to be between $17.150 billion and $17.350 billion, representing growth of 5.2% to 6.4% year-over-year.
Adjusted EBITDA Guidance for 2026: The company anticipates adjusted EBITDA to range between $3.975 billion and $4.025 billion, reflecting growth of 4.9% to 6.3% year-over-year.
Adjusted Diluted EPS Guidance for 2026: IQVIA raised its adjusted diluted EPS guidance to $12.65 to $12.95, representing growth of 6.1% to 8.6% year-over-year.
Second Quarter 2026 Guidance: Revenue is expected to be between $4.280 billion and $4.340 billion, adjusted EBITDA between $955 million and $975 million, and adjusted diluted EPS between $2.98 and $3.08.
Backlog Conversion: IQVIA's backlog reached $34.2 billion, with $8.9 billion expected to convert to revenue in the next 12 months, representing nearly 8% growth year-over-year.
Pipeline Growth: The qualified pipeline grew mid-single digits year-over-year, with RFP flow increasing high single digits, driven by growth in large pharma and emerging biopharma (EVP).
AI Integration and Deployment: IQVIA continues to expand its AI capabilities, with 192 AI agents deployed across 64 use cases. These agents are expected to enhance operational efficiency and client engagement in both Commercial Solutions and R&D Solutions.
Strategic Collaborations: IQVIA announced partnerships with major pharma companies and institutions, including Pfizer, Boehringer Ingelheim, and Duke Clinical Research Institute, to drive innovation and efficiency in clinical trials and commercial operations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: In the quarter, we repurchased $552 million of our shares, which leaves us approximately $1.2 billion of repo authorization remaining under the current program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the impact of service fees versus pass-through bookings on profitability?
A:Pass-throughs have zero profitability drop-through and are irrelevant to profitability. The mix of indications in the quarter led to fewer pass-throughs, which did not impact margins. Service fee bookings were up significantly year-over-year and sequentially.
Q:Are the FSO dynamics and lower pass-throughs a result of customer clinical strategies or other factors?
A:The lower pass-throughs were not due to changes in customer dynamics but rather the specific trials won this quarter. There is no indication of a shift in customer clinical strategies.
Q:What is the outlook for demand in outsourced clinical development?
A:The demand environment is constructive, with no fundamental changes in the drivers of outsourced clinical development. Large sponsors are taking a more deliberate approach to capital deployment, but the environment is stabilizing and improving.
Q:What is driving the growth in Commercial Solutions?
A:Commercial Solutions experienced 5% organic growth, driven by increased demand for AI-driven solutions, new drug launches, and strong performance in analytics, consulting, and patient solutions. AI is creating new demand for services rather than replacing them.
Q:What is the market outlook for large pharma and EVP funding?
A:Large pharma shows a more constructive demand environment, though not fully back to pre-disruption levels. EVP funding reached record levels, indicating renewed confidence in the industry.
Q:What are the drivers of EBITDA margin progression through the year?
A:EBITDA margin progression is consistent with historical trends. FX tailwinds will moderate through the year, and strong productivity programs are expected to result in positive reported margins.
Q:What is the impact of lower pass-throughs on bookings and book-to-bill ratios?
A:Lower pass-throughs reduced reported bookings, but adjusting for this, the book-to-bill ratio would have been approximately 1.15x. This does not impact margins or future growth predictions.
Q:What are the constant dollar organic growth rates for R&DS and Commercial Solutions?
A:R&DS reported 3% organic growth, while Commercial Solutions reported 5% organic growth, resulting in an overall enterprise organic growth rate of 4%.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific timeline for when large pharma demand would return to pre-disruption levels, using general statements about stabilization and improvement instead. Additionally, they did not provide detailed data on the exact mix of recurring versus discretionary revenue in Commercial Solutions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI agent
AI agentification
AI foundation
AI solution
Boehringer
Commercial Solutions
Duke
EVP
IQVIA AI
IQVIA agent
IQVIA agreement
IQVIA contract
IQVIA expertise
apple
capability client
collaboration IQVIA
document
fee booking
level AI
life science
obesity
optimization site
portfolio
protocol optimization
recast
reporting structure
segment reporting
service fee
service trial
site identification
stage program
start
strength
trial design
IQV Transcript
IQVIA Holdings Inc. (IQV) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call reveals strong financial performance with revenue and EPS exceeding guidance, substantial share repurchases, and optimistic outlooks for demand in outsourced clinical development and Commercial Solutions. Despite some economic uncertainties, the constructive demand environment and increased AI-driven demand in Commercial Solutions are positive indicators. Share repurchases and solid cash flow further enhance shareholder value. The Q&A session confirms stable demand and growth drivers, with no significant negative trends highlighted. Overall, the sentiment is positive, likely resulting in a stock price increase of 2% to 8%.
IQVIA Holdings Inc. (IQV) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-12
IQVIA Holdings Inc. (IQV) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-9
IQVIA Holdings Inc. (IQV) Q4 2025 Earnings Call Transcript
Positive2-5
The earnings call summary highlights strong financial performance, including revenue and EPS growth, alongside strategic acquisitions and AI integration. The Q&A section reveals management's confidence in AI as an opportunity rather than a threat, despite some lack of clarity. The company's guidance is optimistic, with no major negative indicators, suggesting a positive stock price reaction.
IQV Slides
IQV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
